Zealand Pharma A/S (ZEAL) 2017年CSR报告「NASDAQ」.pdf

《Zealand Pharma A/S (ZEAL) 2017年CSR报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Zealand Pharma A/S (ZEAL) 2017年CSR报告「NASDAQ」.pdf（13页珍藏版）》请在三个皮匠报告上搜索。

1、 Zealand Pharma A/S Smedeland 36 2600 Glostrup Denmark Statutory report on Corporate Social Responsibility 2017 Statutory report on Corporate Social Responsibility for the financial year 2017,cf.section 99a and 99b of the Danish Financial Statements Act1.This report is a supplement to the Management

2、s review in the Annual Report 2017 covering the period January 1 December 31,2017.1In Danish,Lovpligtig redegrelse for samfundsansvar,jf.rsregnskabsloven 99a og 99b Zealand Pharma A/S;Statutory report on Corporate Social Responsibility 2017 2/13 Corporate Social Responsibility(CSR)Report for 2017 We

3、 believe that operating,as a responsible company that serves broader economic and societal interests will best create value by enabling us to attract and consolidate relations with customers,suppliers,investors and key stakeholders,while attracting and retaining our employees.Zealand Pharma Zealand

4、is a world leader in the discovery and development of peptide therapeutics,focusing on specialty gastrointestinal and metabolic diseases.We have a late-stage program in Phase 3 development and two Phase 3-ready programs,all with potential to launch into major markets:glepaglutide,a long-acting GLP-2

5、 analog for short bowel syndrome,and dasiglucagon,a soluble,stable glucagon analog in liquid formulation in development as three distinct medicines.In 2017,Soliqua 100/33,a fixed-dose combination of the Zealand-invented GLP-1 lixisenatide,and Lantus,was launched in the U.S.by Sanofi and launched as

6、Suliqua in some European countries.Two programs within obesity and/or type 2 diabetes are in Phase 1 development by our partner Boehringer Ingelheim.We aim to advance rare disease programs all the way to market,combined with growth through partnerships,leveraging our validated peptide platform and e